Auris Medical Holding AG (NASDAQ:EARS) shot up 1% on Friday . The company traded as high as $2.08 and last traded at $2.05, with a volume of 386,997 shares trading hands. The stock had previously closed at $2.03.

A number of research firms have recently weighed in on EARS. Leerink Swann reaffirmed a “buy” rating and set a $12.00 price target on shares of Auris Medical Holding AG in a report on Wednesday, June 15th. Jefferies Group reissued a “buy” rating on shares of Auris Medical Holding AG in a report on Friday, June 10th. Zacks Investment Research raised Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a report on Tuesday, July 12th. JMP Securities cut Auris Medical Holding AG from an “outperform” rating to a “market perform” rating in a report on Thursday, August 18th. Finally, Needham & Company LLC boosted their target price on Auris Medical Holding AG from $5.00 to $11.00 and gave the stock a “buy” rating in a report on Friday, August 19th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Auris Medical Holding AG currently has an average rating of “Buy” and a consensus price target of $8.88.

The stock has a 50-day moving average of $3.68 and a 200-day moving average of $3.86. The firm’s market cap is $71.06 million.

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.